FineCross M3 empowers physicians to perform safer PCI procedures, helping improve outcomes in patients with challenging coronary anatomies
Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
Max and Luna personify HRV Pharma’s core values of trust, loyalty, and authentic partnership
IMCD engaged with manufacturers, formulators, and brand leaders, offering valuable insights into evolving consumer trends
States exhorted to ensure rational use of cough syrups, particularly among children, as most coughs are self-limiting and do not require pharmacological treatment
Investment to expand manufacturing and global medicine supply capacity
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
Subscribe To Our Newsletter & Stay Updated
